Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer：a Single Arm，Multi-center，Open-label Study

NCT03346811 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03346811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03346811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer：a Single Arm，Multi-center，Open-label Study
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
November 18, 2017
Completion date
March 10, 2020
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma egfr mutation-positive lung cancer